Florbetaben: 18F-labeled radiotracer used in PET
Florbetaben (Neuraceq)] is an 18F-labeled radiotracer used in PET.
It is currently undergoing global clinical development for use in in vivo mapping of extracellular fibrillar amyloid ß (Aß), a pathological characteristic of Alzheimers disease.
Even though techniques such as FDG-PET and MRI have been successfully applied in the diagnosis of dementia, they are not specific for Alzheimers disease. In recent years, this has led to a quest for more suitable positron-emitting radiotracers, based on the chemistry of dyes used in histological staining. Promising new radiopharmaceuticals, such as the Pittsburgh Compound B (11C-PiB), have been the result. Nevertheless, [11C] cannot be ideally commercialized, so that radiotracers labeled with the more suitable radionuclide [18F], such as Florbetaben, have been intensively evaluated in phases II and III clinical trials.
Please note that Florbetaben is currently only available for clinical trials.
Where to buy
Please order 18F-Florbetaben from our distribution partner Curium Pharma.
Info request about Curium products can be directly sent to Radiopharmaceuticals.Netherlands@curiumpharma.com.
- Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; for the Florbetaben Study Group (2011). Cerebral amyloid-β PET with florbetaben ((18)F) in patients with Alzheimers disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10 (5): 424-435.
- Vallabhajosula S (2011). Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med 41 (4): 283-299.